世界における前立腺がんワクチンの治験動向

PNS Pharmaが発行した調査報告書(PNSP501233)
◆英語タイトル:Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015
◆商品コード:PNSP501233
◆発行会社(リサーチ会社):PNS Pharma
◆発行日:2015年1月
◆ページ数:155
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥169,500見積依頼/購入/質問フォーム
Multi User(社内共有可)USD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はPNS Pharma社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。PNS Pharma社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Prostate cancer has emerged as a disease with one of the highest incidences and mortality rates in males across the world. This situation has created a large unmet medical demand for better therapeutics by patients suffering from prostate cancer due to modest response generated by presently available therapeutics. Hormone based therapeutics and chemotherapeutics helped in improving the patient’s condition but they have side effects and modest pharmacological benefits reflecting necessity for better product. Pharmaceutical companies focused their efforts to resolve this problem by increasing research and development activities by diverging more funds in this segment. As a result, prophylactic prostate cancer vaccine was developed and introduced in market which is going to witness competition from innovative products in next few years.

Prostate cancer vaccine is a recent development which is more potent than presently available prostate cancer therapeutics in providing better medical care. Prophylactic nature of this vaccine makes it possible to prevent the future incidences of prostate cancer. Besides, it can also prevent the relapse, provides long- term immunity, decrease morbidity and mortality rates along with increasing longevity. Owing to these benefits offered by prostate cancer vaccines their acceptance is increasing among patients and physicians in recent years. It is expected that due competition and increased number of products in market will cause decrease in the price of prostate cancer vaccines in coming years.

Prostate cancer vaccine utilizes different antigens like Prostate-Specific Membrane Antigen, Prostate-Specific Antigen (PSA) and Prostatic Acid Phosphatase (PAP) in pharmacological formulations. These antigens are isolated from the prostate tumor and injected into the body to activate the immune cells. They identify these antigens as non-self and begin to search and eliminate cancerous cells from body to prevent proliferation of cancerous cells. Highly specific nature causes elimination of cancerous cells in prostate while sparing normal cells leading to minimized side effects in patients.

Prostate cancer vaccines are prophylactic in nature due to which they can prevent the future incidences of cancer. Immune cells are primed to search and eliminate the cancerous cells due to which they are able to prevent relapse. Circulating cancerous cells are also targeted responsible for secondary cancer development is checked in the body. Efficacy of cancer vaccine could be monitored by checking PSA levels which may indicate improvement in patient’s condition. However, these results may vary from patient to patient but significant improvement has been observed as compared to conventional therapeutic methods. Besides pharmacological benefits, this fact also reflects towards high marketing potential of prophylactic prostate cancer vaccine.

“Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015” Report Highlights:

• Introduction to Prostate Cancer Vaccine
• Mechanism of Prostate Cancer Vaccine
• Global Prostate Cancer Vaccine Clinical Trial Insight by Company, Country & Phase
• Global Prostate Cancer Vaccine Clinical Pipeline: 41 Vaccines
• Majority Prostate Cancer Vaccine in Phase-II: 10 Vaccines
• Marketed Prostate Cancer Vaccine: 1 (Provenge by Dendreon Corporation)

【レポートの目次】

1. Introduction to Prostate Cancer Vaccine

2. Mechanism of Prostate Cancer Vaccine

3. Global Prostate Cancer Vaccine Market Dynamics
3.1 Favorable Market Parameters
3.2 Marketing & Commercialization Challenges

4. Global Prostate Cancer Vaccine Market Outlook
4.1 Current Market Scenario
4.2 Global Prostate Cancer Vaccines Pipeline Overview

5. Global Prostate Cancer Vaccine Market Future Prospects

6. Personalized Cancer Vaccine Market Opportunities

7. Global Prostate Cancer Vaccines Clinical Trial Insight by Company, Country & Phase
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-III

8. Marketed Prostate Cancer Vaccines by Company & Country

9. Suspended & Discontinued Prostate Cancer Vaccines in Clinical Trials
9.1 No Development Reported
9.2 Discontinued
9.3 Suspended

10. Competitive Landscape
10.1 Adamis Pharmaceuticals
10.2 Aduro BioTech
10.3 Bellicum Pharmaceuticals
10.4 CytoVac
10.5 Dendreon Corporation
10.6 Generex Biotechnology Corporation
10.7 Immunovaccine
10.8 Oncbiomune
10.9 Progenics
10.10 Sotio

Figure 1-1: Functions of Prostate Gland
Figure 1-2: Factors Responsible for Increasing Prostate Cancer Incidences
Figure 1-3: Different Methods of Prostate Cancer Treatment
Figure 2-1: Mechanism of Cancer Vaccines
Figure 2-2: Classification of Cancer Vaccines
Figure 2-3: Benefits of Prostate Cancer Vaccines
Figure 3-1: Drivers for Prostate Cancer Vaccines Market
Figure 3-2: Challenges for Prostate Cancer Vaccines Market
Figure 4-1: Prostate Cancer Vaccines Pipeline by Phase (%)
Figure 4-2: Prostate Cancer Vaccines Pipeline by Phase (Number of Drugs)
Figure 4-3: No Development Reported in Prostate Cancer Vaccines Pipeline by Phase (%)
Figure 4-4: No Development Reported in Prostate Cancer Vaccines Pipeline by Phase (Number of Drugs)
Figure 4-5: Discontinued Prostate Cancer Vaccines Pipeline by Phase (%)
Figure 4-6: Discontinued Prostate Cancer Vaccines Pipeline by Phase (Number of Drugs)
Figure 4-7: Suspended Prostate Cancer Vaccines Pipeline by Phase (%)
Figure 4-8: Suspended Prostate Cancer Vaccines Pipeline by Phase (Number of Drugs)
Figure 6-1: Personalized Cancer Vaccines Development Process
Figure 6-2: Personalized Cancer Vaccine Development Methodology
Figure 6-3: Skin Implant for Cancer Vaccine
Figure 10-1: Adamis Pharmaceuticals Pipeline
Figure 10-2: Bellicum Pharmaceuticals Pipeline
Figure 10-3: cytovac Pipeline
Figure 10-4: Generex Biotechnology Clinical Pipeline Overview
Figure 10-5: Immunovaccine Clinical Pipeline Overview

Table 6-1: Different Types of Biomarkers For Personalized Cancer Vaccine Development



【掲載企業】

Adamis Pharmaceuticals, Aduro BioTech, Bellicum Pharmaceuticals, CytoVac, Dendreon Corporation, Generex Biotechnology Corporation, Immunovaccine, Oncbiomune, Progenics, Sotio


【レポートのキーワード】

前立腺がんワクチン、治験、前立腺がん治療薬、製薬

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界における前立腺がんワクチンの治験動向(Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆